Boston Scientific Business Combination, Contingent Consideration, Liability increased by 3.0% to $378.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 121.1%, from $171.00M to $378.00M. Over 4 years (FY 2020 to FY 2024), Business Combination, Contingent Consideration, Liability shows a downward trend with a -3.4% CAGR.
other_business_combination_contingent_consideration_liability| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $312.00M | $448.00M | $486.00M | $456.00M | $219.00M | $182.00M | $149.00M | $93.00M | $107.00M | $119.00M | $404.00M | $273.00M | $293.00M | $171.00M | $171.00M | $214.00M | $367.00M | $378.00M |
| QoQ Change | — | +43.6% | +8.5% | -6.2% | -52.0% | -16.9% | -18.1% | -37.6% | +15.1% | +11.2% | +239.5% | -32.4% | +7.3% | -41.6% | +0.0% | +25.1% | +71.5% | +3.0% |
| YoY Change | — | — | — | — | -29.8% | -59.4% | -69.3% | -79.6% | -51.1% | -34.6% | +171.1% | +193.5% | +173.8% | +43.7% | -57.7% | -21.6% | +25.3% | +121.1% |